<DOC>
	<DOCNO>NCT00635804</DOCNO>
	<brief_summary>This study examine safety , tolerability plasma pharmacokinetics multiple dos MK-3281 healthy male participant Part I , Hepatitis C Virus ( HCV ) -infected male participant Part II . The clinical efficacy MK-3281 , measure viral load reduction , also assess Part II . The primary hypothesis twice daily administration MK-3281 10 day healthy adult male participant 7 day HCV-infected male participant sufficiently safe well tolerate , base assessment clinical laboratory adverse experience , permit continued clinical investigation . The result study guide dose selection future study healthy participant HCV-infected participant .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics MK-3281 Healthy Hepatitis C Infected Male Participants ( MK-3281-002 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Participant judge good/stable health base medical history , physical examination , vital sign , laboratory safety test perform prestudy ( screen ) visit and/or prior administration initial dose study drug Participant clinically significant abnormality electrocardiogram ( ECG ) perform prestudy ( screen ) visit and/or prior administration initial dose study drug Participants female partner ( ) childbearing potential must agree use medically acceptable method contraception study 90 day last dose study drug Participant clinical diagnosis chronic HCV infection ( Part II ) . Participant history stroke , chronic seizure , major neurological disorder Participant history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , immunological , renal , respiratory , genitourinary abnormality diseases Participant history neoplastic disease ( include leukemia , lymphoma , malignant melanoma ) , myeloproliferative disease , regardless time since treatment Participant positive Hepatitis B surface antigen ( evidence active Hepatitis B infection ) prescreening ( study ) visit For Healthy Panel ( Part I ) , participant evidence chronic Hepatitis C virus infection prescreening ( study ) visit Participant history document Human Immunodeficiency Virus ( HIV ) infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>